OS Therapies Inc. terminates its Equity Purchase Agreement with Square Gate Capital Master Fund, LLC - Series 3.
The company gained $4.2 million in gross proceeds through a recent successful warrant exercise inducement and exchange offering.
The monthly burn rate in the second half of 2025 is lower due to the completion of treatment phases in clinical trials.
Financial Update
Termination of Equity Line of Credit and $4.2 million proceeds impact operational funding.
Clinical Trials Progress
Completion of treatment phases in Phase 2b OST-HER2 and Phase 1b OST-504 trials.
Capital Allocation Strategy
Focus on driving towards approval for OST-HER2 in osteosarcoma and analyzing data for OST-504 in prostate cancer.
- OS Therapies aims to allocate capital efficiently for product developments amidst positive trial results.
- The termination of the Equity Purchase Agreement signals a strategic move towards operational sustainability.
The termination of the Equity Line of Credit aligns with OS Therapies' strategic priorities, showcasing a prudent approach to capital management amidst notable clinical trial advancements.